Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biomarin Pharmaceutical Inc BMRN

Healthcare Biotechnology
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BMRN)

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

PR Newswire 6 days ago

BioMarin to Participate in Three Upcoming Investor Conferences

PR Newswire November 6, 2024

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

PR Newswire October 29, 2024

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

GlobeNewswire October 24, 2024

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

PR Newswire October 16, 2024

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

PR Newswire September 18, 2024

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

PR Newswire September 4, 2024

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

PR Newswire September 4, 2024

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

PR Newswire August 29, 2024
View More News ››

Opinion & Analysis (NDAQ:BMRN)

How sick will Brexit make biotech and pharma?

The Life Sciences Report June 29, 2016

The Calandra Report: Watch this hot tub!

Thom Calandra January 10, 2014

Big Pharma has a big problem and merger mania is heating up

Marc Lichtenfeld July 29, 2010
View More Opinion ››

Bullboard Posts (NDAQ:BMRN)

Market Perform Recommendation Issued On BMRN By Bernstein

Breaking News: $BMRN Market Perform Recommendation Issued On BMRN By Bernstein2024-06-04 15:30:03 ET Bernstein analyst issues MARKET...
whytestocks - June 4, 2024

$15 billion biotech stock

there's clearly a wind at the back of this health care company. As a biotech stock that focuses on rare disease gene therapy, BMRN is...
Lisaslab - August 24, 2022

Bulls on Parade

Get ready for the correction; getting close to day 3 
hart.marco - August 21, 2020

Holding Strong

in the face of overall weakness.strong management leads to strong results.great job here!...again,if this was a vancouver,canada bio-tech...
seldomseen1 - March 7, 2008

RE: moving forward

new highs ..here we come.if this was a vancouver biotech(LOL)/managements there would roll this back..they are too funny LOL.
seldomseen1 - February 1, 2008

moving forward

coming off highs,still very strong going forward.
seldomseen1 - January 29, 2008
View more Bullboard ››

FPX Nickel Corp.

FPX Nickel Corp.

FPX Nickel Corp. is a Canada-based junior nickel mining company. The Company is focused on the exploration and development of ...
View More »